Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?

Novartis Pharma said on April 23 that it has filed its chimeric antigen receptor T cell (CAR-T) therapy tisagenlecleucel, known as Kymriah overseas, for certain types of leukemia and lymphoma, marking the first CAR-T submission in Japan. With the filing,...read more